Medical Technology

@techcrunch.com 2 years ago

Flagship Pioneering’s new venture is betting on tRNA to treat “thousands of diseases”

@andresvilarino 3 years ago

#ArtificialIntelligence, like #Algorithms, could crack the language of #cancer & #Alzheimer’s, study finds #AI #HealthCare #HealthTech #DigitalHealth #MedicalTech #MedTech #BioTech #ML #MachineLearning #data https://buff.ly/3mFeCos https://t.co/lvl2otB2Du

@xconomy.com 3 years ago

Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin

@xconomy.com 3 years ago

Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More

@xconomy.com 3 years ago

Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity

@xconomy.com 3 years ago

Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity

@xconomy.com 3 years ago

Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More

@xconomy.com 3 years ago

Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue

@xconomy.com 3 years ago

FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures

@xconomy.com 3 years ago

Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More

@xconomy.com 4 years ago

Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More

@xconomy.com 4 years ago

Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks

@xconomy.com 4 years ago

Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer

@xconomy.com 4 years ago

CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019

@xconomy.com 4 years ago

Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More

@xconomy.com 4 years ago

Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus

@xconomy.com 4 years ago

Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers

@xconomy.com 4 years ago

Schrödinger Sets Course for IPO to Support Growing Internal Pipeline

@xconomy.com 4 years ago

Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic

@xconomy.com 4 years ago

Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal

@xconomy.com 4 years ago

Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More

@xconomy.com 4 years ago

ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More

@xconomy.com 4 years ago

Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?

@xconomy.com 4 years ago

Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone

@xconomy.com 4 years ago

Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More

@techcrunch.com 4 years ago

Google’s SMILY is reverse image search for cancer diagnosis

@xconomy.com 4 years ago

Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More

@xconomy.com 4 years ago

Oncolytics Bio Tacks On Cancer Combo Study with Merck KGaA, Pfizer

@xconomy.com 4 years ago

Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More

@xconomy.com 4 years ago

Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September

@xconomy.com 4 years ago

Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More

@xconomy.com 5 years ago

JLabs’ Luby Takes the Reins at TMC Innovation Institute in Houston

@xconomy.com 5 years ago

Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More

@xconomy.com 5 years ago

Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More

@xconomy.com 5 years ago

Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More

@xconomy.com 5 years ago

San Antonio Develops “Action Plan” to Draw Life Sciences Businesses

@xconomy.com 5 years ago

ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More

@xconomy.com 5 years ago

Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More

@xconomy.com 5 years ago

Synthorx Files for IPO to Advance Enhanced Cytokine Drugs

@xconomy.com 5 years ago

Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More

@xconomy.com 5 years ago

ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front

@xconomy.com 5 years ago

Nobel Medicine Prize Honors Cancer Immunotherapy Pioneers Allison & Honjo

@xconomy.com 5 years ago

IPO Wave Rolls On as Five Life Science Firms Haul in $651M

@xconomy.com 5 years ago

In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine

@xconomy.com 5 years ago

Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More

@xconomy.com 5 years ago

Pfizer, Merck Lead Strata Oncology’s $26M Series B Round

@xconomy.com 5 years ago

OncoNano, Maker of Tumor Imaging Technology, Raises $11.7 Million

@xconomy.com 5 years ago

Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs